drugset / Trial / NCT03232320

Meditoxin® Treatment in Patients With Cervical Dystonia

NCT03232320 ↗

Phase 3 Completed 66 enrolled Medy-Tox
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine the efficacy and safety of Meditoxin in subjects with cervical dystonia compared with placebo (normal saline)

Timeline

Start
2017-07-06
Primary completion
2018-10-31
Completion
2018-11-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Meditoxin Protein / enzyme biologic — —

Indications